Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for IDEAYA Biosciences, Inc. (IDYA : NSDQ)
 
 • Company Description   
IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences Inc. is based in South San Francisco, United States.

Number of Employees: 145

 
 • Price / Volume Information   
Yesterday's Closing Price: $35.40 Daily Weekly Monthly
20 Day Moving Average: 1,107,431 shares
Shares Outstanding: 87.86 (millions)
Market Capitalization: $3,110.28 (millions)
Beta: -0.09
52 Week High: $40.58
52 Week Low: $22.09
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.45% -3.17%
12 Week 21.65% 18.32%
Year To Date 2.40% -3.16%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5000 SHORELINE COURT SUITE 300
-
SOUTH SAN FRANCISCO,CA 94080
USA		 ph: 650-443-6209
fax: -		 investor@ideayabio.com http://www.ideayabio.com
 
 • General Corporate Information   
Officers
Yujiro Hata - Chief Executive Officer and President
Terry Rosen - Chairman of the Board
Joshua Bleharski - Chief Financial Officer
Andres Ruiz Briseno - Chief Accounting Officer
Garret Hampton - Director

Peer Information
IDEAYA Biosciences, Inc. (CORR.)
IDEAYA Biosciences, Inc. (RSPI)
IDEAYA Biosciences, Inc. (CGXP)
IDEAYA Biosciences, Inc. (BGEN)
IDEAYA Biosciences, Inc. (GTBP)
IDEAYA Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45166A102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/04/26
Share - Related Items
Shares Outstanding: 87.86
Most Recent Split Date: (:1)
Beta: -0.09
Market Capitalization: $3,110.28 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.01 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.10 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.32
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -35.37%
vs. Previous Quarter: -18.09%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -39.68%
ROE
06/30/26 - -
03/31/26 - -14.24
12/31/25 - -11.10
ROA
06/30/26 - -
03/31/26 - -13.09
12/31/25 - -10.25
Current Ratio
06/30/26 - -
03/31/26 - 10.74
12/31/25 - 11.34
Quick Ratio
06/30/26 - -
03/31/26 - 10.74
12/31/25 - 11.34
Operating Margin
06/30/26 - -
03/31/26 - -
12/31/25 - -
Net Margin
06/30/26 - -
03/31/26 - -
12/31/25 - -
Pre-Tax Margin
06/30/26 - -
03/31/26 - -62.17
12/31/25 - -51.99
Book Value
06/30/26 - -
03/31/26 - 10.67
12/31/25 - 11.67
Inventory Turnover
06/30/26 - -
03/31/26 - -
12/31/25 - -
Debt-to-Equity
06/30/26 - -
03/31/26 - 0.00
12/31/25 - 0.00
Debt-to-Capital
06/30/26 - -
03/31/26 - 0.00
12/31/25 - 0.00
 

Powered by Zacks Investment Research ©